These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 15827097)

  • 1. Codon-specific development of pheochromocytoma in multiple endocrine neoplasia type 2.
    Machens A; Brauckhoff M; Holzhausen HJ; Thanh PN; Lehnert H; Dralle H
    J Clin Endocrinol Metab; 2005 Jul; 90(7):3999-4003. PubMed ID: 15827097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pheochromocytoma and medullary thyroid carcinoma: a new genotype-phenotype correlation of the RET protooncogene 891 germline mutation.
    Jimenez C; Habra MA; Huang SC; El-Naggar A; Shapiro SE; Evans DB; Cote G; Gagel RF
    J Clin Endocrinol Metab; 2004 Aug; 89(8):4142-5. PubMed ID: 15292360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship.
    Yip L; Cote GJ; Shapiro SE; Ayers GD; Herzog CE; Sellin RV; Sherman SI; Gagel RF; Lee JE; Evans DB
    Arch Surg; 2003 Apr; 138(4):409-16; discussion 416. PubMed ID: 12686527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence and clinical relevance of RET proto-oncogene germline mutations in pheochromocytoma patients.
    Januszewicz A; Neumann HP; Loń I; Szmigielski C; Symonides B; Kabat M; Apel TW; Wocial B; Lapiński M; Januszewicz W
    J Hypertens; 2000 Aug; 18(8):1019-23. PubMed ID: 10953992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peak incidence of pheochromocytoma and primary hyperparathyroidism in multiple endocrine neoplasia 2: need for age-adjusted biochemical screening.
    Machens A; Lorenz K; Dralle H
    J Clin Endocrinol Metab; 2013 Feb; 98(2):E336-45. PubMed ID: 23284010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pheochromocytoma penetrance varies by RET mutation in MEN 2A.
    Quayle FJ; Fialkowski EA; Benveniste R; Moley JF
    Surgery; 2007 Dec; 142(6):800-5; discussion 805.e1. PubMed ID: 18063059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High penetrance of pheochromocytoma associated with the novel C634Y/Y791F double germline mutation in the RET protooncogene.
    Toledo RA; Wagner SM; Coutinho FL; Lourenço DM; Azevedo JA; Longuini VC; Reis MT; Siqueira SA; Lucon AM; Tavares MR; Fragoso MC; Pereira AA; Dahia PL; Mulligan LM; Toledo SP
    J Clin Endocrinol Metab; 2010 Mar; 95(3):1318-27. PubMed ID: 20080836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intronic single nucleotide polymorphisms in the RET protooncogene are associated with a subset of apparently sporadic pheochromocytoma and may modulate age of onset.
    McWhinney SR; Boru G; Binkley PK; Peczkowska M; Januszewicz AA; Neumann HP; Eng C
    J Clin Endocrinol Metab; 2003 Oct; 88(10):4911-6. PubMed ID: 14557473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The clinical patterns and RET proto-oncogene identification of pheochromocytoma in 13 multiple endocrine neoplasia type 2A pedigrees].
    Qi XP; Chen ZG; Jin HY; Li F; Cheng J; Ying RB; Zhao JQ; Guo DG; Luo SY; Chen GP; Zhang XN
    Zhonghua Yi Xue Za Zhi; 2013 Jul; 93(28):2200-4. PubMed ID: 24169328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical spectrum of multiple endocrine neoplasia type 2a caused by the rare intracellular RET mutation S891A.
    Schulte KM; Machens A; Fugazzola L; McGregor A; Diaz-Cano S; Izatt L; Aylwin S; Talat N; Beck-Peccoz P; Dralle H
    J Clin Endocrinol Metab; 2010 Sep; 95(9):E92-7. PubMed ID: 20554711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk-oriented approach to hereditary adrenal pheochromocytoma.
    Machens A; Brauckhoff M; Gimm O; Dralle H
    Ann N Y Acad Sci; 2006 Aug; 1073():417-28. PubMed ID: 17102110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutation analysis of the RET proto-oncogene and early thyroidectomy: results of a Portuguese cancer centre.
    Bugalho MJ; Domingues R; Santos JR; Catarino AL; Sobrinho L
    Surgery; 2007 Jan; 141(1):90-5. PubMed ID: 17188172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrent ipsilateral pheochromocytoma in carriers of RET p.Cys634 missense mutations.
    Machens A; Lorenz K; Weber F; Dralle H
    Endocrine; 2022 Jun; 77(1):160-167. PubMed ID: 35579782
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Management of multiple endocrine neoplasia syndrome type 2 families in association with rare germline mutations of the RET proto-oncogene].
    Fitze G; Saeger HD; Roesner D; Schackert HK
    Klin Padiatr; 2004; 216(5):270-6. PubMed ID: 15455293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Sparing surgery for bilateral pheochromocytoma].
    Shimoyama T; Saito J; Ito Y; Soyama A; Ito H; Nishikawa T; Kakuta Y; Nagata M; Yamaguchi K; Iizuka T
    Nihon Naika Gakkai Zasshi; 2004 Nov; 93(11):2416-8. PubMed ID: 15624479
    [No Abstract]   [Full Text] [Related]  

  • 16. Estimated risk of pheochromocytoma recurrence after adrenal-sparing surgery in patients with multiple endocrine neoplasia type 2A.
    Asari R; Scheuba C; Kaczirek K; Niederle B
    Arch Surg; 2006 Dec; 141(12):1199-205; discussion 1205. PubMed ID: 17178962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple endocrine neoplasia, the old and the new: a mini review.
    Pasquali D; Di Matteo FM; Renzullo A; Accardo G; Esposito D; Barbato F; Colantuoni V; Circelli L; Conzo G
    G Chir; 2012; 33(11-12):370-3. PubMed ID: 23140918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes.
    Benn DE; Gimenez-Roqueplo AP; Reilly JR; Bertherat J; Burgess J; Byth K; Croxson M; Dahia PL; Elston M; Gimm O; Henley D; Herman P; Murday V; Niccoli-Sire P; Pasieka JL; Rohmer V; Tucker K; Jeunemaitre X; Marsh DJ; Plouin PF; Robinson BG
    J Clin Endocrinol Metab; 2006 Mar; 91(3):827-36. PubMed ID: 16317055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patients with RET D631Y mutations most commonly present with pheochromocytoma and not medullary thyroid carcinoma.
    Elston MS; Meyer-Rochow GY; Holdaway I; Conaglen JV
    Horm Metab Res; 2012 May; 44(5):339-42. PubMed ID: 22274720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular implications of RET mutations for pheochromocytoma risk in multiple endocrine neoplasia 2.
    Gujral TS; Mulligan LM
    Ann N Y Acad Sci; 2006 Aug; 1073():234-40. PubMed ID: 17102091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.